MXPA02011513A - Method for identifying medically valuable active substances. - Google Patents

Method for identifying medically valuable active substances.

Info

Publication number
MXPA02011513A
MXPA02011513A MXPA02011513A MXPA02011513A MXPA02011513A MX PA02011513 A MXPA02011513 A MX PA02011513A MX PA02011513 A MXPA02011513 A MX PA02011513A MX PA02011513 A MXPA02011513 A MX PA02011513A MX PA02011513 A MXPA02011513 A MX PA02011513A
Authority
MX
Mexico
Prior art keywords
active substances
protein
valuable active
catalytic domain
medically valuable
Prior art date
Application number
MXPA02011513A
Other languages
Spanish (es)
Inventor
Klaus Ulrich Weithmann
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of MXPA02011513A publication Critical patent/MXPA02011513A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)

Abstract

The invention relates to a method for identifying inhibitors or ligands for binding domains. The inventive method comprises using a protein that has at least one catalytic domain, incubating it with a marker substrate that binds to the catalytic domain of the protein and reacts therewith, with a substrate that can reversibly bind to the catalytic domain and to the binding domain, and with the inhibitor, and detecting whether the protein reacts with the marker substrate.
MXPA02011513A 2000-06-09 2001-05-30 Method for identifying medically valuable active substances. MXPA02011513A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10028204A DE10028204A1 (en) 2000-06-09 2000-06-09 Process for the discovery of medically valuable active substances
PCT/EP2001/006143 WO2001094612A2 (en) 2000-06-09 2001-05-30 Method for identifying medically valuable active substances

Publications (1)

Publication Number Publication Date
MXPA02011513A true MXPA02011513A (en) 2004-09-06

Family

ID=7645007

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011513A MXPA02011513A (en) 2000-06-09 2001-05-30 Method for identifying medically valuable active substances.

Country Status (12)

Country Link
US (1) US6737246B2 (en)
EP (1) EP1294924B1 (en)
JP (1) JP4643887B2 (en)
AT (1) ATE315662T1 (en)
AU (2) AU2001283827B2 (en)
CA (1) CA2411436C (en)
DE (2) DE10028204A1 (en)
DK (1) DK1294924T3 (en)
ES (1) ES2254466T3 (en)
IL (2) IL153221A0 (en)
MX (1) MXPA02011513A (en)
WO (1) WO2001094612A2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8702254D0 (en) * 1987-05-29 1987-05-29 Kabivitrum Ab NOVEL HEPARIN DERIVATIVES
PT93847A (en) * 1989-04-24 1990-11-20 Harvard College PROCESS FOR THE PREPARATION OF OLIGOSACARIDES OF LOW MOLECULAR WEIGHT DERIVED FROM HEPARIN OR DESPOLYMENED HEPARAN SULFATE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
CA1335707C (en) * 1989-08-15 1995-05-30 Pyare Khanna Drug screening assay
US5770691A (en) * 1995-06-05 1998-06-23 Regents Of The University Of Minnesota Discriminatory substrates for MMP hydrolysis

Also Published As

Publication number Publication date
IL153221A0 (en) 2003-07-06
US20020045203A1 (en) 2002-04-18
DE10028204A1 (en) 2002-01-03
CA2411436C (en) 2010-08-17
JP2004503218A (en) 2004-02-05
DK1294924T3 (en) 2006-05-22
ES2254466T3 (en) 2006-06-16
IL153221A (en) 2008-11-26
EP1294924A2 (en) 2003-03-26
EP1294924B1 (en) 2006-01-11
WO2001094612A3 (en) 2002-09-06
AU8382701A (en) 2001-12-17
ATE315662T1 (en) 2006-02-15
DE50108687D1 (en) 2006-04-06
JP4643887B2 (en) 2011-03-02
AU2001283827B2 (en) 2006-01-12
US6737246B2 (en) 2004-05-18
CA2411436A1 (en) 2002-12-05
WO2001094612A2 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
WO2003020880A3 (en) Method of identifying inhibitors of lck
WO2000002917A3 (en) Compounds and methods for modulating cadherin-mediated functions
DK1421389T3 (en) Neurofibril markers
WO2000031124A3 (en) Peptides that modulate the interaction of b class ephrins and pdz domains
DE69939820D1 (en) INTERNALIZING ERBB2 ANTIBODIES
ATE397661T1 (en) BINDING DOMAIN OF THE DELTA PROTEIN
WO2005114219A3 (en) Assays to identify irreversibly binding inhibitors of receptor tyrosine kinases
ATE555202T1 (en) METHOD FOR DELIVERING RNA INTERFERENCE AND USES THEREOF
EP1864998A3 (en) Binding molecules
DE69828682D1 (en) NANOMOLAR, NON-PEPTIDIC INHIBITORS OF CATHEPSIN D
WO2004058821A3 (en) Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EA020464B9 (en) Antibody single variable domains against serum albumin
MX2007002908A (en) Immobilized probes and methods of detecting conformationally altered prion proteins.
WO2008019696A3 (en) Bisubstrate fluorescent probe binding to protein kinases
NO20052553L (en) Cobalaminanalyse.
AU2002239882A1 (en) Method for identifying a ligand for a biological substrate
DE69931928D1 (en) REVERSIBLE INHIBIVING PROBES
FR2853077B1 (en) SOLID PHASE IMMUNOCHROMATOGRAPHIC METHODS
EP1138781A3 (en) Method for Quantifying DNA binding activity of DNA binding proteins
DK1246945T3 (en) Method of identifying a label affixed to a solid body
MXPA02011513A (en) Method for identifying medically valuable active substances.
WO2001072778A3 (en) Method of identifying inhibitors of tie-2
AU2003243375A8 (en) Improved receptor detection
ATE440964T1 (en) METHOD FOR DETECTING POLYNUCLEOTIDE KINASE AND USE THEREOF AS A MARKER
WO2001016300A3 (en) Method of identifying inhibitors of cdc25

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status